The clinical characteristics and treatment outcomes of 174 patients with NSCLC with PD-L1 TPS of ≥50% who received first-line pembrolizumab between February 1, 2017 and April 31, 2018 are summarized in eTable 1 and eFigure 1 in the Supplement, respectively. This evidence concerns the gene CD274 and non-small cell lung carcinoma.